Ritholtz Wealth Management Acquires 1,858 Shares of Danaher Corporation $DHR

Key Points

• Ritholtz Wealth Management increased its stake in Danaher Corporation by 28.7%, acquiring an additional 1,858 shares, bringing its total holdings to 8,327 shares worth approximately $1.645 million.
• A number of institutional investors, including Nuveen LLC and Invesco Ltd., have significantly increased their holdings in Danaher, with institutional investors collectively owning 79.05% of the company's stock.
• Analysts have set new price targets for Danaher, with a range from $220.00 to $250.00 and a consensus rating of "Moderate Buy," indicating positive sentiment towards the stock.

Ritholtz Wealth Management increased its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 28.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,327 shares of the conglomerate's stock after buying an additional 1,858 shares during the quarter. Ritholtz Wealth Management's holdings in Danaher were worth $1,645,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in DHR. Nuveen LLC purchased a new position in shares of Danaher in the first quarter worth approximately $833,941,000. Invesco Ltd. boosted its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after buying an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock worth $295,550,000 after buying an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP boosted its holdings in shares of Danaher by 33.2% in the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock worth $651,515,000 after buying an additional 791,662 shares during the last quarter. Finally, Parnassus Investments LLC boosted its holdings in shares of Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock worth $784,745,000 after buying an additional 722,636 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on DHR. Weiss Ratings reissued a "hold (c-)" rating on shares of Danaher in a report on Wednesday, October 8th. Rothschild & Co Redburn restated a "neutral" rating and set a $220.00 target price (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Guggenheim restated a "buy" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Redburn Partners set a $220.00 target price on shares of Danaher in a research note on Wednesday, October 8th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $244.60.

Danaher Trading Up 2.3%

Danaher stock opened at $210.86 on Friday. The stock has a market cap of $150.99 billion, a P/E ratio of 44.86, a PEG ratio of 2.94 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.41. The firm's 50 day moving average price is $201.43 and its 200-day moving average price is $197.23.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 11.10% of the stock is currently owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.